Alison Ghosh
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 11
- Genetics 3
- Genetic Associations and Epidemiology 3
- Journals
- The Lancet (6 papers)JAMA (5 papers)Nature (3 papers)British journal of surgery (1 paper)The Lancet Global Health (1 paper)
- Partner nations
- United KingdomVietnamAustralia
In The Last Decade
Alison Ghosh
20 papers receiving 2.7k citations
Alison Ghosh's Hit Papers
Peers
Comparison fields: 5 of 73
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 30
- Emergency Medical Services 59
- Internal Medicine 22
- Pulmonary and Respiratory Medicine 186
Countries citing papers authored by Alison Ghosh
This map shows the geographic impact of Alison Ghosh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Ghosh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Ghosh more than expected).
Fields of papers citing papers by Alison Ghosh
This network shows the impact of papers produced by Alison Ghosh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Ghosh. The network helps show where Alison Ghosh may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 5 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 6 | 2021 | 213 | |
| 7 | 2021 | 166 | |
| 8 | 2016 | 145 | |
| 9 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 10 | 2017 | 112 | |
| 11 | 2022 | 105 | |
| 12 | 2022 | 100 | |
| 13 | 2023 | 84 | |
| 14 | 2021 | 72 | |
| 15 | 2023 | 60 | |
| 16 | 2023 | 46 | |
| 17 | 2023 | 34 | |
| 18 | 2021 | 31 | |
| 19 | 2019 | 20 | |
| 20 | 2024 | 8 |
About Alison Ghosh
Alison Ghosh is a scholar working on Infectious Diseases, Genetics, Emergency Medical Services, Pulmonary and Respiratory Medicine and Nutrition and Dietetics, having authored 20 papers that have together received 2.9k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (11 papers), Genetic Associations and Epidemiology (3 papers), Respiratory Support and Mechanisms (2 papers), Patient Safety and Medication Errors (1 paper) and Vitamin C and Antioxidants Research (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (30 citations), Emergency Medical Services (59 citations), Internal Medicine (22 citations) and Pulmonary and Respiratory Medicine (186 citations). Alison Ghosh has collaborated with scholars based in United Kingdom, Vietnam and Australia. Their work appears in journals such as The Lancet, JAMA, Nature, British journal of surgery and The Lancet Global Health.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.